<DOC>
	<DOCNO>NCT00003923</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use light drug make cancer cell sensitive light kill tumor cell . This may effective treatment cancer bile duct , gallbladder , pancreas . PURPOSE : Phase II trial determine effectiveness photodynamic therapy treat patient cancer bile duct , gallbladder , pancreas .</brief_summary>
	<brief_title>Photodynamic Therapy Treating Patients With Cancer Bile Duct , Gallbladder , Pancreas</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety efficacy photodynamic therapy use porfimer sodium patient unresectable malignant bile duct obstruction . OUTLINE : Patients stratify accord tumor location ( proximal v distal ) . Patients receive porfimer sodium IV 3-5 minute day 1 , follow percutaneous endoscopic laser light treatment day 3 . Patients achieve partial response complete response accompany increase total bilirubin cholangitis may repeat treatment maximum 3 course . Patients follow weekly 1 month , monthly 1 year . PROJECTED ACCRUAL : Approximately 30 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Dihematoporphyrin Ether</mesh_term>
	<mesh_term>Trioxsalen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove malignant bile duct obstruction obstructive jaundice Primary carcinoma bile duct , gallbladder , pancreas OR Metastatic bile duct disease Successful insertion percutaneous drain endoscopic stent Unresectable disease OR Resectable disease refusal surgery Prior biliary plastic metallic stent allow , require stent replacement due recurrent jaundice routine plastic stent change No erosion biliary tumor major blood vessel No evidence bile duct perforation PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin least 2 mg/dL Renal : Not specify Other : No history allergies hypersensitivity porphyrins No porphyria No cholangitis pancreatitis PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy brachytherapy abdomen Surgery : See Disease Characteristics Other : No prior concurrent experimental investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>cholangiocarcinoma gallbladder</keyword>
	<keyword>cholangiocarcinoma extrahepatic bile duct</keyword>
	<keyword>adult primary cholangiocellular carcinoma</keyword>
</DOC>